pCPA Activity Overview
Status | Total Negotiations | Summary |
---|---|---|
Active Negotiations | 37 | Non-oncology: 26 Oncology: 11 |
Under Consideration for Negotiation | 18 | Non-oncology: 9 Oncology: 9 |
Completed Negotiations | 853 | With Letter of Intent: 741 Without agreement: 112 |
Negotiations That Were Not Pursued | 111 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
Brand Name | Manufacturer | Indication | Engagement Date |
---|---|---|---|
Tysabri | Biogen Canada Inc. | Multiple Sclerosis, Relapsing-Remitting | |
Mavenclad | EMD Serono Canada, a division of EMD Inc. | Multiple Sclerosis, Relapsing-Remitting | |
Wegovy | Novo Nordisk Canada Inc. | Weight Management | |
Dupixent | Sanofi-Aventis Canada Inc. | Severe chronic rhinosinusitis with nasal polyps | |
Dupixent | Sanofi-Aventis Canada Inc. | Prurigo nodularis | |
Tagrisso | AstraZeneca Canada Inc. | For the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in co | |
Signifor LAR | Recordati Rare Diseases Canada Inc. | Acromegaly in Adults | |
Rybrevant | Janssen Inc. | In combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, who |